BAUDETTE, Minn., Sept. 27, 2016 /PRNewswire/ -- ANI
Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the
launch of Erythromycin Ethylsuccinate for Oral Suspension 200mg/5mL
indicated as a treatment for various infections. The current
annual U.S. market for this product is approximately $78 million, according to IMS Health, and is
representative of two brand products. ANI will immediately
launch the product.
Arthur S. Przybyl, ANI's
President and CEO stated, "This is the first product that we are
launching from the basket of 22 previously marketed generic
products that we acquired in July
2015 and it represents another successful manufacturing site
transfer and re-commercialization of a previously discontinued ANDA
product. ANI has added nine new products to our commercial
portfolio in 2017 and we continue to forecast the launch of at
least one additional generic product this year."
About Erythromycin Ethylsuccinate for Oral
Suspension
Erythromycin Ethylsuccinate for Oral Suspension is indicated in
the treatment of infections caused by susceptible strains of
selected diseases. For more information, including the complete
list of indications and usages, please see the accompanying Full
Prescribing Information.
About ANI
ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an
integrated specialty pharmaceutical company developing,
manufacturing, and marketing branded and generic prescription
pharmaceuticals. The Company's targeted areas of product
development currently include narcotics, oncolytics (anti-cancers),
hormones and steroids, and complex formulations involving extended
release and combination products. For more information, please
visit our website www.anipharmaceuticals.com.
Forward-Looking Statements
To the extent any statements made in this release deal with
information that is not historical, these are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements include, but are not limited
to, statements about price increases, the Company's future
operations, products financial position, operating results and
prospects , the Company's pipeline or potential markets therefor,
and other statements that are not historical in nature,
particularly those that utilize terminology such as "anticipates,"
"will," "expects," "plans," "potential," "future," "believes,"
"intends," "continue," other words of similar meaning, derivations
of such words and the use of future dates.
Uncertainties and risks may cause the Company's actual results
to be materially different than those expressed in or implied by
such forward-looking statements. Uncertainties and risks include,
but are not limited to, the risk that the Company may face with
respect to importing raw materials; increased competition;
acquisitions; contract manufacturing arrangements; delays or
failure in obtaining product approval from the U.S. Food and Drug
Administration; general business and economic conditions; market
trends; products development; regulatory and other approvals and
marketing.
More detailed information on these and additional factors that
could affect the Company's actual results are described in the
Company's filings with the Securities and Exchange Commission,
including its most recent annual report on Form 10-K and quarterly
reports on Form 10-Q, as well as its proxy statement. All
forward-looking statements in this news release speak only as of
the date of this news release and are based on the Company's
current beliefs, assumptions, and expectations. The Company
undertakes no obligation to update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
For more information about ANI, please contact:
Investor Relations
IR@anipharmaceuticals.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ani-pharmaceuticals-announces-launch-of-erythromycin-ethylsuccinate-for-oral-suspension-200mg5ml-300334595.html
SOURCE ANI Pharmaceuticals, Inc.